Evidence map›Paper›PMID 33704770›Full record

ReviewEuropean journal of immunology2021

Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy.

Connie B Gilfillan, Michael Hebeisen, Nathalie Rufer, Daniel E Speiser

Abstract readReview
In one paragraph

Review in European journal of immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Renaissance of antiviral CD8Nature reviews. Immunology · 2026
    Review
  2. Influenza-Induced CD103ImmunoHorizons · 2022
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Connie B GilfillanDepartment of Oncology, University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-5574-1143
Michael HebeisenDepartment of Oncology, University Hospital and University of Lausanne, Lausanne, Switzerland.
Nathalie RuferDepartment of Oncology, University Hospital and University of Lausanne, Lausanne, Switzerland.
Daniel E SpeiserDepartment of Oncology, University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-2031-3250

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The functional avidity (FA) of cytotoxic CD8 T cells impacts strongly on their functional capabilities and correlates with protection from infection and cancer. FA depends on TCR affinity, downstream signaling strength, and TCR affinity-independent parameters of the immune synapse, such as costimulatory and inhibitory receptors. The functional impact of coreceptors on FA remains to be fully elucidated. Despite its importance, FA is infrequently assessed and incompletely understood. There is currently no consensus as to whether FA can be enhanced by optimized vaccine dose or boosting schedule. Recent findings suggest that FA is remarkably stable in vivo, possibly due to continued signaling modulation of critical receptors in the immune synapse. In this review, we provide an overview of the current knowledge and hypothesize that in vivo, codominant T cells constantly "equalize" their FA for similar function. We present a new model of constant FA regulation, and discuss practical implications for T-cell-based cancer immunotherapy.

Indexed as

AnimalsCancer VaccinesCD8-Positive T-LymphocytesHumansImmunizationImmunological SynapsesImmunotherapy, AdoptiveModels, ImmunologicalNeoplasmsProtein BindingReceptors, Antigen, T-CellSignal TransductionT-Lymphocytes, CytotoxicCancer VaccinesReceptors, Antigen, T-Cellavidity regulationCD8 T cellscoreceptorsfunctional avidityTCR affinity

Identifiers

PMID33704770
PMCPMC8252569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.